Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Additional Compliance Grace Period
Rhea-AI Summary
Cellyan Biotechnology (Nasdaq: HKPD) announced it received a Nasdaq notice granting an additional 180 calendar days, until January 11, 2027, to regain compliance with Nasdaq’s $1.00 minimum closing bid price requirement under Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market.
To regain compliance, Cellyan must achieve and maintain a closing bid price of at least $1.00 per Class A ordinary share for a minimum of ten consecutive business days within the extension period. Nasdaq’s determination reflects that the company currently satisfies all other applicable initial listing criteria, including market value of publicly held shares. The company indicated it plans to pursue all feasible compliance measures and may, if necessary, implement a reverse share split. The notice does not currently affect the listing status of HKPD shares, which continue to trade normally on Nasdaq.
Positive
- 180-day Nasdaq compliance extension granted to January 11, 2027
- Meets all other Nasdaq Capital Market initial listing criteria except Minimum Bid Price
- HKPD shares continue trading uninterrupted on Nasdaq under ticker “HKPD”
- Company signals intent to cure deficiency, including potential reverse share split
Negative
- Currently non-compliant with Nasdaq $1.00 Minimum Bid Price Requirement
- No assurance it can regain or maintain Nasdaq listing compliance by January 11, 2027
Market reaction after Nasdaq bid-price compliance extension: HKPD -11.73% in the Jul 17 session
In the Jul 17 session, HKPD declined 11.73%, reflecting a significant negative market reaction. Argus tracked a peak move of +34.6% during that session. Argus tracked a trough of -22.1% from its starting point during tracking. Our momentum scanner triggered 42 alerts that day, indicating elevated trading interest and price volatility. Trading volume was exceptionally heavy at 68.3x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 16 | Nasdaq deficiency notice | Negative | +0.0% | Nasdaq notified noncompliance with $1.00 bid-price requirement and granted cure period. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The prior Nasdaq bid-price deficiency notice drew almost no price reaction, suggesting limited historical sensitivity to listing-compliance headlines.
Key Terms
minimum bid price requirement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
HONG KONG, July 16, 2026 (GLOBE NEWSWIRE) -- Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) (the "Company"), a leading provider of over the counter (“OTC”) pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced that it received a notification letter (the “Notification Letter”) on July 14, 2026 from Nasdaq's Listing Qualifications Department indicating that the Company has been granted an additional 180 calendar day period, or until January 11, 2027, to regain compliance with the Nasdaq’s minimum
The Company will coordinate all feasible compliance solutions to restore listing compliance within the designated timeframe and safeguard the interests of all shareholders. However, there can be no assurance that the Company will be able to maintain compliance with the Nasdaq Capital Market’s continued listing requirements or regain compliance with the Minimum Bid Price Requirement.
Nasdaq’s determination is based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and the Company’s written notice of its intention to cure the deficiency during the second compliance period and if necessary, by effecting a reverse share split. The notification letter has no effect at this time on the listing of the Company's class A ordinary shares, which will continue to trade uninterrupted on Nasdaq under the ticker “HKPD.”
About Cellyan Biotechnology Co., Ltd
Cellyan Biotechnology Co., Ltd (f.k.a. Hong Kong Pharma Digital Technology Holdings Limited) offers two main categories of services: (i) OTC pharmaceutical cross-border e-commerce supply chain services through its Hong Kong subsidiary, Joint Cross Border Logistics Company Limited (“Joint Cross Border”), and (ii) OTC pharmaceutical cross-border procurement and distribution through its Hong Kong subsidiary, V-Alliance Technology Supplies Limited.
Through its engagement with OTC pharmaceutical suppliers, logistics companies, and merchants on Chinese e-commerce platforms, Joint Cross Border provides a convenient one-stop solution for Mainland Chinese customers seeking access to OTC pharmaceutical products outside Mainland China. Joint Cross Border’s comprehensive service offerings include pre-consultation, product information review, procuring overseas OTC pharmaceutical products, enlisting products with the Hong Kong Department of Health, obtaining import and export permits, storing products, packaging, and arranging logistics and end-to-end delivery services for customers.
Forward-Looking Statements
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. All forward-looking statements, expressed or implied, in this release are based only on information currently available to us and speak only as of the date on which they are made. Investors can find many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may" or other similar expressions in this release. Except as otherwise required by applicable law, we disclaim any duty to publicly update any forward-looking statement to reflect events or circumstances after the date of this release. These statements are subject to uncertainties and risks, including, but not limited to, the uncertainties related to market conditions, and other factors discussed in our filings with the SEC. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's filings with the SEC. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
For investor and media inquiries please contact:
Cellyan Biotechnology Co., Ltd
Media Contact: andy@cell-yan.com
Investor Relations: stella@cell-yan.com
